[["short-term 3,5,3'-triiodothyroacetic acid (TRIAC) therapy", "is effective for", "the treatment of hyperthyroidism caused by thyroid hormone resistance (RTH)"], ["the patient", "carries", "a P453T mutation in the gene encoding the thyroid hormone receptor beta (THRB)"], ["treatment with up to 3.0 mg TRIAC per day", "achieved", "reduction in thyroid volume"], ["treatment with up to 3.0 mg TRIAC per day", "achieved", "resolution of supraventricular arrhythmia"], ["treatment with up to 3.0 mg TRIAC per day", "achieved", "decrease in thyroid-stimulating hormone (TSH) levels"], ["treatment with up to 3.0 mg TRIAC per day", "achieved", "decrease in free-thyroxine (FT4) levels"], ["ADHD symptoms", "improved", "during TRIAC treatment"], ["ADHD Rating Scale score", "declined", "with improvement in ADHD symptoms"], ["TRIAC pharmacokinetic study", "demonstrated", "TRIAC disappears from circulation rapidly"], ["TRIAC pharmacokinetic study", "demonstrated", "TRIAC has a shorter duration of TSH secretion inhibitory effect in RTH patient compared to control"], ["studies of TSH and FT4 levels", "indicated", "the TRIAC effect is dose dependent"], ["TRIAC", "was effective and safe in", "ameliorating the effects of hyperthyroidism and ADHD symptoms in a child with known genetic RTH"], ["TRIAC", "has", "a short half-life"], ["TRIAC", "functions", "dose dependently"]]